Éva Malpass
Zilver Vena stent shows three-year patency across patient groups
Cook Medical’s Zilver Vena venous self-expanding stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular...
Sonablate announces first patient enrolled in clinical trial for ablation of...
Sonablate has announced the first patient enrolled in the HIFIVE clinical trial in the USA under the guidance of principal investigator, Naiem Nassiri (The...
Mechanical thrombectomy shifts the needle toward interventional management of PE and...
This advertorial is sponsored by Inari Medical.
Evaluating the current standard of care for the management of acute pulmonary embolism (PE) and deep vein thrombosis...
Research suggests potential link between strenuous physical activity and increased VTE...
Published in the Journal of Thrombosis and Thrombolysis, new research with a follow-up of 27 years has found an association between high levels of...
Surmodics receives US FDA 510(k) clearance for Pounce XL thrombectomy system
Surmodics has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance for its Pounce XL thrombectomy system.
The Pounce XL thrombectomy...
B Braun receives US FDA clearance for deep access intravenous catheter
B Braun recently announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Introcan Safety 2 deep access intravenous...
Argon Medical announces launch of peripheral venous thrombectomy system
Argon Medical has today announced the launch of the Cleaner Vac thrombectomy system for the removal of blood clot from the peripheral venous vasculature.
The...
Deep venous stenting determined “safe” with low rates of major complications
A recent analysis of deep venous stent placement has determined that the procedure is safe with low rates of major complications. Published in the...
Study reveals improved COVID-19-associated VTE outcomes in post-vaccine period
A recent study published in the Journal of Thrombosis and Thrombolysis has revealed a significant decrease in the incidence of mortality and major bleeding in...
Jupiter Endovascular announce US FDA approval for SPIRARE II pivotal trial
Jupiter Endovascular has announced that the US Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for the SPIRARE II US pivotal study. The pivotal trial will...
Obvius Robotics receives US FDA Breakthrough Device designation for CERTA central...
Obvius Robotics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for its CERTA access system for central...
New randomised data show cyanoacrylate glue performs strongly on patient satisfaction
Patients undergoing cyanoacrylate glue closure for superficial venous disease reported higher periprocedural satisfaction than those who were treated via surgical stripping, data from a...
Prosthetic valve implantation shows “vast” improvements in deep chronic venous insufficiency
“The surgical challenges of repairing deep venous reflux have been present for more than a generation. It is worth reflecting on the fact that...
New randomised data show cyanoacrylate glue performs strongly on patient satisfaction
Patients undergoing cyanoacrylate glue closure for superficial venous disease reported higher periprocedural satisfaction than those who were treated via surgical stripping, data from a...
One-year results for synchronous anterior accessory saphenous vein ablation hold up
Twelve-month results from the SYNCHRONOUS trial, which is evaluating the role of prophylactic anterior accessory saphenous vein (AASV) ablation for the prevention of recurrent...
Penumbra announces FDA clearance of Lightning Flash 2 for the treatment...
Penumbra has announced the US Food and Drug Administration (FDA) clearance and launch of Lightning Flash 2, the next generation computer assisted vacuum thrombectomy (CAVT)...
Review urges development of protocols to reduce hypersensitivity reactions after cyanoacrylate...
Despite being considered “generally safe”, cyanoacrylate can cause local reactions in up to 25% of patients, disproportionately affecting women, Asian race and thin patients...
Biolitec announces two new devices in the ELVeS radial portfolio
Biolitec recently announced that it has extended its ELVeS Radial laser system for the minimally invasive laser treatment of insufficient veins by two further...
FLAME, FLASH and ongoing PEERLESS trials collect “compelling” data for FlowTriever...
Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism...
JETi registry provides “remarkable results” for peripheral thrombectomy system
Presenting “remarkable results” from the JETi registry—a prospective, multicentre, observational study which collected real-world data on the safety, performance and clinical benefits of the...
Study finds anatomic positioning and physical activity type can cause device...
A recent multicentre, prospective study has found that stent deformations are greater in the common iliac vein with higher levels of hip flexion, as...
Analysis of varicose vein registry finds women benefit from endovenous ablation...
An evaluation of the Vascular Quality Initiative’s (VQI) Varicose Vein Registry (VVR) carried out by the Midwestern Vascular Surgical Society (MVSS) has found women...
Meta-analysis of PTS finds one in five risk of long-term symptoms...
A meta-analysis is first to report the pooled risk of post-thrombotic syndrome (PTS) after isolated distal deep vein thrombosis (DVT). Researchers revealed a one...
Boston Scientific announces investment to acquire majority stake of Acotec Scientific
Boston Scientific has announced that it will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares...
Real-world analysis confirms benefit of Xarelto in treating CAT as apixaban
Head-to-head observational analysis showed Xarelto as effective in treating cancer-associated thromboembolism (CAT) as apixaban.
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced observational...